Apixaban metabolism and pharmacokinetics after oral administration to humans N Raghavan, CE Frost, Z Yu, K He, H Zhang, WG Humphreys, D Pinto, ... Drug metabolism and disposition 37 (1), 74-81, 2009 | 798 | 2009 |
Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247 … DJP Pinto, MJ Orwat, S Koch, KA Rossi, RS Alexander, A Smallwood, ... Journal of medicinal chemistry 50 (22), 5339-5356, 2007 | 516 | 2007 |
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by … P Schmiedlin-Ren, DJ Edwards, ME Fitzsimmons, K He, KS Lown, ... Drug Metabolism and Disposition 25 (11), 1228-1233, 1997 | 488 | 1997 |
Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice K He, KR Iyer, RN Hayes, MW Sinz, TF Woolf, PF Hollenberg Chemical research in toxicology 11 (4), 252-259, 1998 | 420 | 1998 |
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies L Wang, D Zhang, N Raghavan, M Yao, L Ma, CA Frost, BD Maxwell, ... Drug Metabolism and Disposition 38 (3), 448-458, 2010 | 308 | 2010 |
Metabolism and disposition of dasatinib after oral administration to humans LJ Christopher, D Cui, C Wu, R Luo, JA Manning, SJ Bonacorsi, M Lago, ... Drug metabolism and disposition 36 (7), 1357-1364, 2008 | 213 | 2008 |
Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved K He, RE Talaat, WF Pool, MD Reily, JE Reed, AJ Bridges, TF Woolf Drug Metabolism and Disposition 32 (6), 639-646, 2004 | 140 | 2004 |
Characterization of efflux transporters involved in distribution and disposition of apixaban D Zhang, K He, JJ Herbst, J Kolb, W Shou, L Wang, PV Balimane, YH Han, ... Drug Metabolism and Disposition 41 (4), 827-835, 2013 | 135 | 2013 |
Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486) K He, TF Woolf, PF Hollenberg Journal of Pharmacology and Experimental Therapeutics 288 (2), 791-797, 1999 | 128 | 1999 |
Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans D Zhang, K He, N Raghavan, L Wang, J Mitroka, BD Maxwell, RM Knabb, ... Drug metabolism and disposition 37 (8), 1738-1748, 2009 | 123 | 2009 |
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants PYS Lam, CG Clark, R Li, DJP Pinto, MJ Orwat, RA Galemmo, JM Fevig, ... Journal of medicinal chemistry 46 (21), 4405-4418, 2003 | 120 | 2003 |
Bergamottin contribution to the grapefruit juice–felodipine interaction and disposition in humans TC Goosen, D Cillié, DG Bailey, C Yu, K He, PF Hollenberg, PM Woster, ... Clinical Pharmacology & Therapeutics 76 (6), 607-617, 2004 | 110 | 2004 |
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor K He, JM Luettgen, D Zhang, B He, JE Grace, B Xin, DJP Pinto, PC Wong, ... European journal of drug metabolism and pharmacokinetics 36, 129-139, 2011 | 98 | 2011 |
Sulfation of o-demethyl apixaban: enzyme identification and species comparison L Wang, N Raghavan, K He, JM Luettgen, WG Humphreys, RM Knabb, ... Drug metabolism and disposition 37 (4), 802-808, 2009 | 82 | 2009 |
Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4 K He, LM Bornheim, AM Falick, D Maltby, H Yin, MA Correia Biochemistry 37 (50), 17448-17457, 1998 | 76 | 1998 |
Tissue distribution and elimination of [14C] apixaban in rats L Wang, K He, B Maxwell, SJ Grossman, LM Tremaine, WG Humphreys, ... Drug Metabolism and Disposition 39 (2), 256-264, 2011 | 74 | 2011 |
Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor. K He, B He, JE Grace, B Xin, D Zhang, DJ Pinto, JM Luettgen, RM Knabb, ... Blood, The Journal of the American Society of Hematology 108 (11), 910-910, 2006 | 72 | 2006 |
Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats K He, MW Lago, RA Iyer, WC Shyu, WG Humphreys, LJ Christopher Drug Metabolism and Disposition 36 (12), 2564-2570, 2008 | 66 | 2008 |
Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an … D Zhang, CE Frost, K He, AD Rodrigues, X Wang, L Wang, TC Goosen, ... Drug Metabolism and Disposition 41 (4), 906-915, 2013 | 65 | 2013 |
1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl) methyl-[1, 1′]-biphen-4-yl]-1, 4, 5, 6-tetrahydropyrazolo-[3, 4-c]-pyridin-7-one (BMS … DJP Pinto, MJ Orwat, ML Quan, Q Han, RA Galemmo Jr, E Amparo, ... Bioorganic & medicinal chemistry letters 16 (15), 4141-4147, 2006 | 62 | 2006 |